Why Does Exercise Guard Against Cancer? Inflammation May Play a Role Bookmark

Excerpt from The New York Times:

“One of the most important benefits of exercise is in how it reduces our risk of developing a number of types of cancer — especially colorectal cancer, which according to some estimates is the malignancy most influenced by physical activity. But how workouts guard against colon cancer remains largely unknown. Physical activity speeds the movement of waste through the intestines, as anyone who has had to hunt for a bathroom during a workout knows. But this does not seem to fully account for the protective effects of exercise. Instead, a small study published in February in The Journal of Physiology suggests we should also look to changes in our bloodstream after exercise.”

Go to full article published by The New York Times on April 22, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Personalizing Precision Medicine with Combination Therapies Improves Outcomes in Cancer Bookmark

Excerpt:

“Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in Nature Medicine  on April 22, 2019, University of California San Diego School of Medicine researchers found that treating patients with personalized, combination therapies improved outcomes in patients with therapy resistant cancers.”

Go to full article published by UC San Diego Health on April 22, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid Tumors Bookmark

Excerpt:

“In patients with malignant pleural disease, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated clinical benefit with no significant toxicity, outcomes that may be due to the regional delivery of the CAR T cells to the intrapleural cavity rather than conventional systemic delivery. The phase I trial (ClinicalTrials.gov identifier: NCT02414269) results were presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting, held March 29–April 3 in Atlanta, Georgia (abstract CT036).”

Go to full article published by Cancer Network on April 10, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Expands Pembrolizumab Indication for First-Line Treatment of NSCLC (Tps ≥1%) Bookmark

Excerpt:

“On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test.

“Pembrolizumab was previously approved as a single agent for the first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 TPS ≥50%.”

Go to full article published by the U.S. Food and Drug Administration on April 11, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pembrolizumab Shows Durable Benefit as Third-Line Treatment of Advanced Small Cell Lung Cancer Bookmark

Excerpt:

“Pembrolizumab demonstrated antitumor activity and induced durable responses in patients with advanced small cell lung cancer who had received two or more previous lines of therapy, according to pooled data from two KEYNOTE trials presented at American Association for Cancer Research Annual Meeting.”

Go to full article published by Healio on April 3, 2019

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer Bookmark

Excerpt:

“On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer.

Approval was based on the IMpower133 study, a randomized (1:1), multicenter, double-blind, placebo-controlled trial in 403 patients with extensive-stage small cell lung cancer who received no prior chemotherapy for extensive stage disease and had ECOG performance status 0 or 1.”

Go to full article published by The ASCO Post on March 19, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Atezolizumab/Nab-Paclitaxel Approved by the FDA for PD-L1+ TNBC Bookmark

Excerpt:

“An accelerated approval has been granted by the FDA for the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a frontline treatment for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).

“The approval is based on the phase III IMpassion130 trial, in which the addition of the PD-L1 inhibitor atezolizumab to nab-paclitaxel reduced the risk of progression or death by 40% compared with nab-paclitaxel alone in this patient population.”

Go to full article published by Targeted Oncology on March 8, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma Bookmark

Excerpt:

“A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be treated with anti–PD-1 drugs before surgery—also showed that immune responses brought on by this therapy can peak as early as 7 days after treatment—much earlier than previous studies have shown. These findings were published by Huang et al in Nature Medicine.”

Go to full article published by The ASCO Post on March 7, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

New Study Suggests Diet May Affect Response To Cancer Immunotherapy Drugs Bookmark

Excerpt:

“People with a type of skin cancer who consumed a high-fiber diet responded better to immunotherapy treatment than those with poorer diets, according to data presented at a media preview of the American Association for Cancer Research (AACR) annual meeting.

“Melanoma is a type of skin cancer which although very treatable if caught early, still kills approximately 9,000 Americans a year, mainly people who are diagnosed a more advanced stage of disease where the cancer has spread to other parts of the body.”

Go to full article published by Forbes on Feb 27, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.